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Abstract. 
 
PDZ motifs are modular protein–protein in-
teraction domains, consisting of 80–120 amino acid resi-
dues, whose function appears to be the direction of in-
tracellular proteins to multiprotein complexes. In 
skeletal muscle, there are a few known PDZ-domain 
proteins, which include neuronal nitric oxide synthase 
and syntrophin, both of which are components of the 
dystrophin complex, and actinin-associated LIM pro-
tein, which binds to the spectrin-like repeats of 
 
a
 
-acti-
nin-2. Here, we report the identiﬁcation and character-
ization of a new skeletal muscle protein containing a 
PDZ domain that binds to the COOH-terminal region 
of 
 
a
 
-actinin-2. This novel 31-kD protein is speciﬁcally 
expressed in heart and skeletal muscle. Using antibod-
ies produced to a fragment of the protein, we can show 
its location in the sarcomere at the level of the Z-band 
by immunoelectron microscopy. At least two proteins, 
32 kD and 78 kD, can be detected by Western blot anal-
ysis of both heart and skeletal muscle, suggesting the 
existence of alternative forms of the protein. In fact, 
several forms were found that appear to be the result
of alternative splicing. The transcript coding for this
Z-band alternatively spliced PDZ motif (ZASP) pro-
tein maps on chromosome 10q22.3-10q23.2, near the lo-
cus for infantile-onset spinocerebellar ataxia.
Key words: skeletal muscle • sarcomeres • muscle 
proteins • immunoelectron microscopy • alternative 
splicing
 
P
 
DZ
 
 motifs (Kennedy, 1995), previously known as
GLGF repeats (Cho et al., 1992) or DHR domains
(Woods and Bryant, 1991), are protein–protein
interaction domains (Sheng, 1996; Brenman and Bredt,
1997; Kornau et al., 1997; Xia et al., 1997) composed of 80–
120 amino acid residues, which can be present as single or
multiple copies (Cho et al., 1992). These domains were
first identified in, and named after, the three members of
the membrane-associated guanylate kinase homologues
(MAGUKs): PSD-95, Dlg, and ZO-1. PDZ domains can
be involved in different types of interactions. NH
 
2
 
-termi-
nal PDZ domains can bind to the COOH-terminal of tar-
get proteins (Kim et al., 1995, Kornau et al., 1995; Sato et
al., 1995). For example, the NH
 
2
 
-terminal of two PDZ do-
mains of PSD-95 and other MAGUK family members can
bind to the COOH-terminal (consensus sequence T/SXV)
 
of Shaker-type K
 
1
 
 channels (Kim et al., 1995) and of
the modulatory subunits (NR2) of N-methyl-D-aspartate
(NMDA) type-glutamate receptor ion channels (Kornau et
al., 1995; Niethammer et al., 1996). In this type of interac-
tion, PDZ domains would appear to be involved in the
targeting and clustering of membrane proteins. In another
type of interaction, PDZ domains can also bind internal
peptides. This is demonstrated by the binding of the PDZ
motif of inactivation no afterpotential D (INAD) to an in-
ternal peptide of the transient-receptor potential (TRP)
calcium channel (Shieh and Zhu, 1996). In a third type of
interaction, PDZ domains can interact with each other in
homomeric PDZ–PDZ interactions, as exemplified by the
binding of the second PDZ domain of PSD-95 and that of
syntrophin to the NH
 
2
 
-terminal PDZ domain of nNOS
(Brenman et al., 1996). It is noteworthy that both the sec-
ond PDZ domain of PSD-95 and the PDZ domain of neu-
ral nitric oxide synthase (nNOS) also can bind COOH-ter-
minal sequences (Schepens et al., 1997; Stricker et al.,
1997), these interactions being mediated by distinct re-
gions of the same PDZ domain. Another type of interac-
tion is portrayed by the PDZ domain of the actinin-associ-
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ated LIM protein (ALP)
 
1
 
 binding to the spectrin-like
repeats of 
 
a
 
-actinin-2 (Xia et al., 1997). Recently, a novel
type of PDZ interaction has been noted with the LIM do-
main, where the second PDZ domain of protein tyrosine
phosphate-BL (PTP-BL) and the PDZ domain of rever-
sion induced LIM (RIL) can bind to the LIM domain of
RIL (Cuppen et al., 1998).
A general function of PDZ domains seems to be direct-
ing cellular proteins to multiprotein complexes. In skeletal
muscle there a few PDZ domain proteins, these include
neuronal nitric oxide synthase and the family of syntro-
phins (Ponting and Phillips, 1995), both of which are com-
ponents of the dystrophin complex (Adams et al., 1993;
Brenman et al., 1995), and ALP, which binds to the spec-
trin-like repeats of 
 
a
 
-actinin-2 (Xia et al., 1997). In this pa-
per, we describe a new alternatively spliced skeletal mus-
cle protein of 31 kD that has an NH
 
2
 
-terminal PDZ
domain for which we propose the name ZASP: Z-band al-
ternatively spliced PDZ motif protein.
 
Materials and Methods
 
Antibodies
 
A cDNA fragment of human ZASP lacking 165 bp from the 5
 
9 
 
end of the
coding sequence was inserted into the His-tag prokaryote expression vec-
tor pQE9 (QIAGEN Inc.) and sequenced to confirm that there were no
significant changes from the original transcript. Human 
 
a
 
-actin cDNA was
obtained by reverse transcriptase PCR using primers based on the se-
quence data present in the Genbank/EMBL/DDBJ database. The result-
ing full-length cDNA was inserted into the pQE9 vector and sequenced to
detect any changes from the known sequence. Both actin and ZASP were
expressed as recombinant proteins in 
 
Escherichia coli
 
 and purified by af-
finity chromatography using nickel-nitrilotriacetic acid resin as specified
by the manufacturer (QIAGEN Inc.). The recombinant ZASP protein
contains a 12-amino acid residue tag plus 228 amino acids of the ZASP
protein (81% of the full-length protein) with an estimated molecular
weight of 26,664 D. The human recombinant 
 
a
 
-actin protein contains 12-
amino acid residues of the tag plus the 377-amino acid residues of the full-
length 
 
a
 
-actin with an estimated molecular weight of 43,449 D. The
 
a
 
-actin and the ZASP recombinant proteins were used to immunize rab-
bits and mice for the production of polyclonal (pAb) and monoclonal
(mAb) antibodies.
 
Construction and Screening of Human and Mouse 
Skeletal Muscle cDNA Libraries
 
Human cDNA libraries suitable for the identification of full-length tran-
scripts were produced using a kit obtained from Invitrogen Corp. The pro-
cedure was given in detail in Valle et al. (1997). A mouse diaphragm
cDNA library Uni-ZAP™XR vector (cat. 937303) used for isolation of
the mouse ZASP was purchased from Stratagene. The screening was done
by PCR and the transcript-specific primers were designed on mouse ex-
pressed sequence tags (ESTs) similar to the human transcript. DNA se-
quencing was carried out directly on 2 
 
m
 
l of the PCR reactions using either
Dye-deoxy-terminator chemistry or Dye-primer chemistry (PE Applied
Biosystems) and run on an ABI377 DNA sequencer (PE Applied Biosys-
tems).
 
Culture of Primary Myoblasts
 
Primary human myoblasts (CHQ5B) were isolated from the quadriceps of
a newborn child (5-d postnatal), without any indication of neuromuscular
disease and the protocols used for this work were in full agreement with
the current legislation on ethical rules. The number of myoblast divisions
noted are from the isolation of the cells. These primary cells can achieve
 
55–60 divisions before reaching proliferative senescence. The prolifera-
tion medium used was F10-Ham (GIBCO BRL) supplemented with 20%
FCS (GIBCO) and 50 
 
m
 
g/ml gentamycin. To obtain differentiated cells,
the growth medium was replaced with DME (GIBCO BRL) without se-
rum plus 10 
 
m
 
g/ml of insulin (I-5500; Sigma Chemical Co.) and 100 
 
m
 
g/ml
of transferrin (T-2036; Sigma Chemical Co.). Myotubes can be detected
two days after the addition of this medium and continue to develop for at
least another four days.
 
Genomic Mapping
 
The genomic mapping was performed by PCR with the radiation hybrids
method, using the GeneBridge 4 whole-genome radiation hybrid panel
(Research Genetics Inc.) consisting of 93 genomic DNA preparations
from human-on-hamster somatic cell lines (Walter et al., 1994). The
screening results were processed by the RHMAPPER software program,
available from the Whitehead Institute/MIT Center for Genomic Re-
search (Cambridge, MA).
 
Immunoelectron Microscopy
 
Heart and skeletal muscle fibers were stretched, fixed for 2 h in 4%
paraformaldehyde plus 0.05% glutaraldehyde, and then dehydrated. The
temperature was decreased stepwise while simultaneously increasing the
concentration of ethanol to minimize the formation of aggregates and
the dislocation of cellular components during dehydration. Then, the sam-
ples were embedded in lowicryl resin K4M (Sigma Chemical Co.) and
ultrathin sections (0.1 
 
m
 
m) of lowicryl embedded samples were cut and
processed. The muscle sections were blocked in 1% BSA plus 0.05%
Tween-20 for 1 h, and then treated with mouse pAb to the recombinant
ZASP protein used at a 1/25 dilution for heart and a 1/50 dilution for skel-
etal muscle samples. The secondary antibody, anti-mouse IgG whole mol-
ecule conjugated with 5-nm gold particles (G7527; Sigma Chemical Co.),
was used at a 1/20 dilution. The sections were counterstained with 3% ura-
nyl acetate for 5 min, washed, and then stained with lead citrate for 45 s.
After further washing, the sections were visualized using a transmission
electron microscope (Zeiss 255/230).
 
Immunofluorescence Microscopy
 
Frozen sections (
 
z
 
5-
 
m
 
m thick) were prepared from human skeletal mus-
cle (Vastus) and mouse heart and skeletal muscle using a Leica Jung/CM/
1800 cryostat. These sections were used for indirect immunofluorescence
experiments by fixing in acetone for 5 min and then blocking in PBS con-
taining 1% BSA and 0.05% Tween-20 for 1 h. Then, they were incubated
at room temperature for 1 h in mouse anti-ZASP antibody and/or a rabbit
anti–
 
a
 
-actin antibody (A2668; Sigma Chemical Co.) used at 1/30- and
1/40-fold dilutions, respectively. The sections were then washed five times
with buffer (PBS, 0.1% BSA, 0.05% Tween-20). TRITC-labeled goat
anti–mouse immunoglobulin (T7657; Sigma Chemical Co.) and/or an
FITC-labeled goat anti–rabbit immunoglobulin (F0511; Sigma Chemical
Co.) were used as second antibodies. Then the slides were incubated in
the second antibody for 1 h at room temperature, washed extensively, and
mounted. Photographs were taken at 40
 
3
 
.
Primary human myoblasts were grown on collagen-coated coverslips
and undifferentiated and differentiated cells were fixed with paraformal-
dehyde (3%), then treated with 0.1 M glycine, and permeabilized with
0.05% Tween-20 for 30 min. The cells were treated with 1% BSA to block
any nonspecific binding. All wash and dilution buffers contained PBS,
BSA 1%, and 0.05% Tween-20. For these experiments, the secondary an-
tibody was FITC-conjugated anti-mouse immunoglobulin (F4018; Sigma
Chemical Co.). All commercial immunochemicals were diluted as recom-
mended by the suppliers. The cells were mounted using Vectashield
mounting medium H-1000 (Vector Laboratories). An Axiovert 35 fluores-
cence microscope (Zeiss) was used at 40
 
3
 
 to view and photograph the
slides of the cell cultures.
 
Immunoprecipitation
 
Polyadenylated mRNAs (D6098-15, D6098-25, D6064-15, and D6064-25;
Invitrogen) of adult and fetal heart, as well as adult and fetal skeletal mus-
cle, were translated in vitro using a reticulocyte lysate system (Promega
Corp.) and labeled with [
 
35
 
S]methionine (Nycomed Amersham Inc.).
Equal amounts of labeled proteins were mixed with the appropriate anti-
body and immunoprecipitated using protein A–Sepharose (Nycomed
Amersham Inc.) in a buffer containing 50 mM Hepes, pH 8.0, 250 mM
 
1. 
 
Abbreviations used in this paper:
 
 ALP, actinin-associated LIM protein;
EST, expressed sequence tag; pAb, polyclonal antibody; ZASP, Z-band
alternatively spliced PDZ motif. 
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NaCl, 0.1% NP-40. The resulting immunoprecipitated samples were run
on 12 (see Fig. 5 C) or 15% (see Fig. 5 B) SDS-polyacrylamide gels. After
running, the gels were dried and put against super resolution type SR
Packard phosphor screens. The screens were analyzed on a Packard Cy-
clone phosphor imager. Rainbow 
 
14
 
C-methylated protein molecular
weight marker (Nycomed Amersham Inc.), with proteins ranging from
220 to 14.3 kD, were used in all the immunoprecipitation experiments.
The mouse anti-ZASP antibody, preimmune sera, and the generic myosin
antibody (MF 20) were used at a dilution of 1/75 for the immunoprecipita-
tion experiments.
 
Northern Blot Analysis
 
The Northern blot analysis of ZASP transcript expression was performed
on human and mouse filters supplied by CLONTECH Laboratories, Inc.
The following filters were used: 7765-1, containing 2 
 
m
 
g/lane of mRNA
from the following eight human muscle tissues: skeletal muscle, uterus (no
endometrium), colon (no mucosa), small intestine, bladder, heart, stom-
ach, and prostate; 7760-1, containing 2 
 
m
 
g/lane of mRNA from the follow-
ing eight human tissues: heart, brain, placenta, lung, liver, skeletal muscle,
kidney, and pancreas; 7762-1, containing 2 
 
m
 
g/lane of mRNA from the fol-
lowing mouse tissues: testis, kidney, skeletal muscle, liver, lung, spleen,
brain, and heart; and 7780-1, containing 1 
 
m
 
g/lane of mRNA from the fol-
lowing twelve human tissues: brain, heart, skeletal muscle, colon, thymus,
spleen, kidney, liver, small intestine, placenta, lung, peripheral blood, and
leukocytes.
The hybridization protocol and solutions were provided by CLON-
TECH Laboratories, Inc. (ExpressHyb Hybridization Solution, cat.
S0910). Probes were obtained either by labeling PCR fragments by ran-
dom priming (DECAprimeII™ DNA labeling kit, Ambicon, cat. 1455)
with 
 
32
 
P-dCTP, or by SP6 transcription (Strip-EZ™ RNA, Ambicon, cat.
1366) with 
 
32
 
P-UTP.
 
Sequence Analysis
 
Sequence similarity searches were performed using the programs
BLASTN, BLASTP, and TBLASTN 2.0.6 (Altschul et al., 1997) with non-
redundant nucleotide and protein databases, as well as with human and
mouse EST databases, running on the NCBI BLAST server (Bethesda,
MD). The FASTA program (Pearson and Lipman, 1988) was run using
EMBL and SwissProt databases. The protein sequences of ZASP and
KIAA0613 were used to search the PROSITE database (Hofmann et al.,
1999) using ScanProsite software (ExPASy Molecular Biology World
Wide Web server, Swiss Institute of Bioinformatics, Geneva, Switzer-
land). These protein sequences were also employed in searching various
databases of functional profiles, using ProfileScan (World Wide Web
server, Bioinformatics Group, ISREC, Switzerland), SMART (Schultz et
al., 1998), and Pfam (Bateman et al., 1999).
 
Western Blotting and Quantitation
 
Human muscle and heart extracts used in Western blot experiments were
obtained by homogenizing fragments of frozen tissue under liquid nitro-
gen using a mortar and pestle. The resulting frozen powder was solubi-
lized in a urea buffer (8 M urea) and then centrifuged to remove any insol-
uble material. The extracts were run on 15% SDS-polyacrylamide gels (10 
 
m
 
g
of total protein per lane). Proteins from different human tissues (brain,
heart, kidney, lung, skeletal muscle, liver, placenta, ovary, testis, and
spleen) were obtained from CLONTECH Laboratories Inc. (cat. 7800–
7808 and 7813) and used at various protein concentrations (10–60 
 
m
 
g of
total protein). The ZASP mAbs and pAbs were used undiluted and at var-
ious dilutions (1/200 and 1/20,000, respectively). The myosin mAb MF 20
developed by Dr. D.A. Fischman was obtained from the Developmental
Studies Hybridoma bank maintained by the University of Iowa’s Depart-
ment of Biological Sciences (Iowa City, IA). MF 20 is a generic myosin an-
tibody obtained as an ascites fluid, which was used at a 1/10,000 dilution.
Goat anti–mouse immunoglobulin conjugated with alkaline phosphatase
(A3562; Sigma Chemical Co.) was used as the second antibody. As de-
tailed previously (Valle et al., 1997), the intensity of the signal obtained
from Western blot analysis can be used to estimate the relative amount of
a specific protein in heart and skeletal muscle extracts. This procedure
was used to estimate the amount of human 
 
a
 
-actin (see Fig. 4 A) and
ZASP protein (see Fig. 4 B) present in total heart and skeletal muscle.
The mouse pAbs to ZASP and 
 
a
 
-actin were used at dilutions of 1/20,000
and 1/4,000, respectively. A prestained wide-range color molecular weight
marker (C3437; Sigma Chemical Co.) was used in all the Western blot ex-
periments. The batch used had the following colors associated to the mo-
lecular weight marker: 205 kD, blue; 126 kD, turquoise; 83 kD, pink; 48 kD,
yellow; 28 kD, orange; 22 kD, green; 15 kD, purple; and 9.5 kD, blue.
 
Yeast Two-hybrid Experiments
 
Unless otherwise specified, the recipes and protocols used for yeast cul-
ture were obtained from Ausubel et al. (1994). The cDNA fragment en-
coding the NH
 
2
 
 terminus (amino acid residues 1–107) of the human ZASP
protein was amplified by PCR using a forward (KpnI 686 PDZ-FOR
GGGGTACCCCGGATGTCTTACAGTGTGACCCTGA) and a re-
verse (SalI 686 PDZ-REV ACGCGTCGACGTTCTGGTGAGGG-
ATCACCG) oligonucleotide incorporating restriction sites KpnI and
SalI, respectively. The amplified product was digested and cloned into the
KpnI–SalI cut vector pHybLex/Zeo (Invitrogen) to create a hybrid pro-
tein between the LexA DNA binding domain and the PDZ domain of
ZASP. This construct was verified by DNA sequencing before it was
used to transform (Agatep et al., 1998) the yeast strain L40 (genotype
 
MATa his3
 
D
 
200 trp1-901 leu2-3112 ade2 LYS2:(4lexAop-HIS3) URA3::
(8lexAop-lacZ) GAL4
 
). The background, due to histidine leakage, was
measured by plating the transformed yeast on YC-HUK plates containing
300 
 
m
 
g/ml of Zeocin (Z300) and a range of 3-Aminotriazole (0, 1, 3, and 5
mM). No histidine expression could be detected after 5 d at 30
 
8
 
C from
plates with 1, 3, and 5 mM 3-Aminotriazole. Several transformants were
tested for the expression of the bait by Western blot assay using both anti-
ZASP pAb and mAb, as well as anti-Lex antibody (Santa Cruz Biotech-
nology). Yeast cells from the best clone were transformed with three dif-
ferent libraries: human heart and skeletal muscle cDNA libraries fused to
the GAL4 activation domain (CLONTECH Laboratories Inc.) and the
third library of human heart cDNA fused to the B42 activation domain
(Display System Biotech). The transformants made with the GAL4 librar-
ies were plated onto 50 YC-LHUK Z300 plates (150-mm diam) and those
obtained with the B42 were plated onto 50 YC-WHUK Z300 plates (150-mm
diam). The growing clones were recovered from three to ten days at 30
 
8
 
C
and the lacZ expression measured by the 
 
b
 
-galactosidase filter assay. Pos-
itive clones were selected, the activating insert was amplified, and the
PCR product was sequenced.
 
Results
 
Molecular Cloning and Characterization of
ZASP mRNA
 
Many novel genes have been discovered from the system-
atic sequencing of human skeletal muscle ESTs carried out
in one of our laboratories (Lanfranchi et al., 1996), includ-
ing telethonin (Valle et al., 1997), which is bound, as well
as phosphorylated, by titin and located at the level of the
Z-band (Mayans et al., 1998; Mues et al., 1998). Currently,
 
.
 
30,000 ESTs have been identified, representing well over
4,000 different independent transcripts. Amongst these,
transcript HSPD00686, hereafter named ZASP, appeared
to be particularly interesting, as it was found at a moder-
ately high frequency (0.06%) and, from a preliminary
study based on reverse transcriptase-PCR, seemed to be
expressed only in heart and skeletal muscle.
ZASP was initially identified in our laboratory as a clus-
ter of muscle ESTs corresponding to the 3
 
9
 
 terminus of the
mRNA; then we isolated and sequenced the entire human
and mouse ZASP transcripts by screening full-length mus-
cle cDNA libraries and performing 5
 
9
 
 RACE experiments
on muscle mRNA. The total length of the nucleotide se-
quence shown in Fig. 1 is 1,607 bases for human and 1,469
bases for mouse. The translation of the human sequence
reveals an open reading frame of 849 bases, encoding a pu-
tative protein of 283 amino acids with a molecular weight
of 30,998 D, whereas the open reading frame of mouse 
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ZASP encodes 288 amino acids and has a molecular
weight of 31,426 D. The human and mouse coding se-
quences are very similar; there is a single insertion of 15
bases (five amino acid residues: Ala, Ser, Pro, Leu, and
Ala) in mouse, and 69 base substitutions between mouse
and human, resulting in eight changes in amino acid
residues, as can be seen in Fig. 1 (Val
 
®
 
Ile, Thr
 
®
 
Ser,
Val
 
®
 
Ala, Ala
 
®
 
Val, Ile
 
®
 
Val, Ser
 
®
 
Thr, Asn
 
®
 
Ser,
Phe
 
®
 
Tyr). Thus, the identity of human and mouse ZASP
is 92% at the nucleotide level and 97% at the amino acid
level.
An extensive similarity search that was done using the
coding sequences (nucleotide and amino acid) of human
ZASP revealed a significant similarity to KIAA0613, both
at the nucleotide and amino acid level. The KIAA0613
sequence (GenBank/EMBL/DDBJ accession number
AB014513) was found as a cDNA clone from brain as part
of a systematic sequencing project (Ishikawa et al., 1998).
A PDZ domain was detected at the NH
 
2
 
-terminal of
ZASP, from amino acid 1 to 85 by the ProfileScan,
SMART, and Pfam programs as described in Materials
and Methods. PredictProtein (Rost et al., 1994), Psort
Figure 1. cDNA and amino
acid sequences of human and
mouse ZASP. The start and
stop codons are in bold char-
acters and the polyadenyla-
tion sites are underlined. In
the coding part of the mouse
sequence, the conserved nu-
cleotides and amino acids are
represented by dots. Dashes
indicate gaps that have been
inserted to align the two se-
quences. The sequence data
are available from Genbank/
EMBL/DDBJ under the ac-
cession number AJ133766
and AJ005621, respectively,
for human and mouse. The
two variant forms of ZASP,
described in the other sec-
tions of this paper, are avail-
able under accession num-
ber AJ133768 and AJ133767,
as well as at http://grup.
bio.unipd.it/muscle. 
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(Nakai and Kanehisa, 1992), and SMART programs did
not detect any transmembrane domain in the ZASP pro-
tein.
Genomic mapping was done using the radiation hybrid
technique, as described in Materials and Methods, reveal-
ing that the ZASP gene maps near the locus for infantile-
onset spinocerebellar ataxia (OMIM 271245) on the hu-
man chromosome region 10q22.3-23.2, with a significant
lod score of 17.
 
ZASP Is Primarily Expressed in Heart and
Skeletal Muscle
 
Northern blot analysis of different tissues using the 3
 
9
 
 un-
translated region of ZASP as a probe revealed that skele-
tal muscle is the major site of expression of this gene (Fig.
2, A and B). It is also expressed in heart, but to a lesser de-
gree. A major band was detected at 1.9 kb in human heart
and skeletal muscle, and at 
 
z
 
1.6 kb in mouse heart and
skeletal muscle (Fig. 2 C). Smaller transcripts could also
be seen in pancreas and placenta at 
 
z
 
1 kb, the signal in
pancreas being quite strong. When Northern blot analysis
of different human tissues was done using as a probe at the
5
 
9 
 
end of ZASP (Fig. 2 D), three transcripts of 1.9 kb, 4 kb,
and 5.4 kb were detected both in heart and skeletal mus-
cle. A weak signal could also be detected in brain, at 
 
z
 
6 kb.
Western blot analysis was done to determine the elec-
trophoretic mobility and tissue distribution of ZASP.
From the results using human tissue (Fig. 3 A), it can be
seen that ZASP is present to a lesser extent in heart than
in skeletal muscle tissue. ZASP has the same pattern of
distribution in mouse tissue as in human, that is, it is pre-
dominantly found in skeletal muscle and, to a lesser ex-
tent, in heart (data not shown). When the ZASP antibody
is used at high dilutions (1/20,000) it detects two bands
(Fig. 3 A). A prominent lower band corresponds to a mo-
lecular weight of 
 
z
 
32 kD and an upper band of 
 
z
 
78 kD.
However, on using twofold higher amounts of total human
protein (20 
 
m
 
g per lane) and 100-fold more concentrated
antibody (1/200 dilution), extra bands can be detected in
both heart and skeletal muscle (Fig. 3 B) with apparent
molecular weights of 22, 27, and 67 kD. Also, there are
two extra proteins that can be detected only in heart (43
and 83 kD). Several human tissues (brain, heart, kidney,
lung, skeletal muscle, liver, placenta, ovary, testis, and
spleen) were screened by Western blotting using a high
concentration of ZASP antibody (1/200 dilution) as the
probe. To detect bands in tissues other than heart and
skeletal muscle, six times more protein had to be used
(60 
 
m
 
g), as well as high concentration of antibody. Under
these conditions, bands could be detected in brain and pla-
centa (Fig. 3 B). Four bands corresponding to proteins of
 
z
 
198, 175, 38, and 20 kD could be detected in brain, and
one band corresponding to a protein of 43 kD in placenta.
Figure 2. Northern blot analysis of human (A, B, and D) and
mouse (C) tissues demonstrating patterns of expression of ZASP
mRNAs. Blots containing Poly(A)1 RNA from a variety of hu-
man and mouse tissues were probed with 39 untranslated region
of ZASP (A–C) or with the 59 region (D) as indicated. The
ZASP transcript is expressed primarily in skeletal muscle and
heart. The numbers on the side indicate size in kb.
Figure 3. (A) Western blot analysis of heart and skeletal muscle
tissue with antibodies to myosin, ZASP, and preimmune sera.
Equal amounts of proteins were run in each lane (10 mg) on a
15% SDS-polyacrylamide gel and then blotted onto Immobilon-P
membrane. The ZASP mAb was used undiluted, whereas the
pAb was used at 1/20,00 dilution, as were the preimmune and
myosin sera. (B) Tissue distribution of ZASP as demonstrated by
Western blotting. Protein extracts from human heart and skeletal
muscle (10 mg), as well as from brain, lung, and placenta (60 mg)
were loaded in each lane, run on a 15% SDS-polyacrylamide gel,
and then blotted. The membrane was probed with mouse pAb
specific for ZASP and preimmune mouse sera, both used at 1/200
dilution. Sigma Chemical Co. color molecular weight markers
were used. 
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The bands seen at low dilutions (1/200) with the poly-
clonal ZASP antibody do not appear to be cross-reactions
to bacterial proteins, as these bands were not removed by
preadsorption of the antiserum with an acetone powder of
the bacteria used for the recombinant protein production
(data not shown). It is possible that the extra bands seen at
low dilutions could be due to cross-reactions with alterna-
tive forms of the ZASP protein, or with other PDZ-con-
taining proteins present in muscle, e.g., ALP (39 kD) and
the syntrophins (58–60 kD). It is interesting to note that
the complex pattern of proteins seen in Western blotting
with low dilutions of polyclonal antiserum (Fig. 3 B) was
also seen with ZASP mAb (data not shown).
Since ZASP does not contain any cysteine residues, the
higher forms, seen when using more protein and a higher
concentration of antisera, are unlikely to be due to ho-
modimer formation. Also, the proteins were run on SDS-
PAGE under denaturing conditions in the presence of
high amounts of DTT. The adsorption of ZASP antisera
with either the 32 or 78 kD protein had only the effect of
reducing the affinity of the preadsorbed antisera for both
proteins, not one in particular (data not shown), with the
ratio of the proteins remaining the same, thus suggesting
that the anti-ZASP antibody recognizes an epitope, which
is also present in the 78-kD protein.
To have an estimate of the level of ZASP present in
muscle tissue, we employed a method (Valle et al., 1997)
based on the intensity of the signal obtained from Western
blot analysis to determine the relative amount of a specific
protein in tissue extracts. This procedure was used to esti-
mate the amount of human 
 
a
 
-actin (Fig. 4 A) and ZASP
(Fig. 4 B) present in 2.5 and 10 
 
m
 
g of total heart and skele-
tal muscle protein, respectively. There is less ZASP pres-
ent in heart than in skeletal muscle tissue: 4.5 ng as op-
posed to 18 ng in 10 
 
m
 
g of total proteins, which is 0.05 and
0.18%, respectively. From densitometric analysis of the
bands, it can be calculated that the actin signal from 2.5 
 
m
 
g
of total muscle proteins is approximately equivalent to 500
ng of recombinant 
 
a
 
-actin. Therefore, using this method
the percentage of actin present in heart and skeletal mus-
cle would be 
 
z
 
20%, which is in agreement with the per-
centage (19%) previously found in adult rabbit muscle
(Pollard, 1981). This method only gives an estimate of the
amount of protein present in muscle tissues, based on two
main assumptions: that proteins of the same size, blotted
under the same conditions have the same rate of blotting;
and that the antibody used has the same affinity for the na-
tive and recombinant proteins. However, within these lim-
its it gives a reasonable approximation of the percentage
of an unknown recombinant protein present in muscle
tissue.
The pattern of expression of ZASP and its ability to
coimmunoprecipitate other muscle proteins was studied
using immunoprecipitation of total human muscle proteins
obtained by in vitro translation of muscle mRNA. In Fig.
5, B and C, for both adult and fetal proteins, immunopre-
cipitation using preimmune sera is shown in lane 1, anti-
ZASP antibody in lane 2, and antimyosin antibody in lane
3. Both the 32 and 78 kD proteins could be immunoprecip-
itated from in vitro translated proteins of adult and fetal
skeletal muscle using the ZASP antibody (Fig. 5 B, lane 2).
Also, from in vitro translated fetal skeletal muscle, three
other proteins of 
 
z
 
43, 50, and 72 kD could be immunopre-
cipitated (Fig. 5 B, lane 2). The 32-kD ZASP protein was
immunoprecipitated, along with proteins of 14.3, 40, and
50 kD, from total adult heart proteins using anti-ZASP an-
tibody (Fig. 5 C, lane 2), whereas in fetal heart (Fig. 5 C,
lane 2) only proteins of 26, 40, and 50 kD could be de-
tected. Therefore, it would appear that the 32-kD protein
is not detectable in fetal heart. It is clear that there is more
ZASP present in skeletal muscle than in heart, this data
being confirmed by both Western blot analysis and these
immunoprecipitation experiments. The amount of ZASP
immunoprecipitated from in vitro translated fetal skeletal
muscle was much less than that from adult, which would
indicate that ZASP is present at very low levels in fetal tis-
sue. This variation was not due to poor translation of fetal
mRNAs, as can be seen by the total protein obtained from
in vitro translation (Fig. 5 A), for both heart and skeletal
muscle.
Myosin mAb was used in the immunoprecipitation ex-
periments as a positive control. It immunoprecipitated a
protein of 
 
z
 
220 kD from the in vitro translated adult and
fetal skeletal muscle proteins, as well as from adult and fe-
tal heart proteins. Both myosin and ZASP antibodies im-
munoprecipitated a protein of 14.3 kD from adult heart
proteins.
 
Localization of ZASP Protein in Human Muscle Cells
 
Immunofluorescence experiments were undertaken in pri-
mary human myoblasts (Fig. 6 A) and myotubes (Fig. 6 B),
as well as skeletal (Fig. 6 C) and heart muscle tissues, with
the scope of detecting the intracellular localization of the
ZASP protein. A fluorescence signal can be detected in
some, but not all, of the primary undifferentiated muscle
cells incubated with ZASP antibodies. The fluorescence is
usually restricted to the pseudopodia and to the area of
the cytoplasm around the nuclei (Fig. 6 A), where it can be
seen as strongly fluorescing dots. The fluorescence inten-
sity in individual cells may be similar in differentiated and
Figure 4. (A) Western blot
analysis of known amounts
of recombinant human a-actin
(left) and known amounts of
total protein (2.5 mg) from
human heart and skeletal
muscle tissue (right). Actin
was detected using a mouse
pAb specific for human
a-actin. (B) Western blot
analysis of known amounts
of recombinant ZASP protein (left) and known amounts of total
protein (10 mg) from human heart and skeletal muscle tissue
(right). The recombinant protein lacks some amino acids from
the NH2-terminal end of the ZASP sequence, therefore it is
slightly smaller in size than the native muscle protein. Mouse
pAb to ZASP was used to detect the protein. From densitometric
analysis of the bands, it can be calculated that the actin signal
from 2.5 mg of total muscle proteins (both heart or skeletal mus-
cle) is approximately equivalent to 500 ng of purified a-actin,
whereas for ZASP, there is less protein present in heart than
skeletal muscle tissue: 4.5 ng, as opposed to 18 ng in 10 mg of total
muscle proteins.Faulkner et al. ZASP: A New Skeletal Muscle Protein 471
undifferentiated cells, but the strong fluorescence seen in
the undifferentiated cells is restricted to a small percent-
age of the total cells (5–10%), whereas in differentiated
cells, the percentage is much higher (90%). In differenti-
ated cells incubated with antibodies to ZASP, a fluores-
cent signal can be detected in nearly all of the cells and it is
especially strong throughout the myotubes (Fig. 6 B). In
these cells, cross-striations can be seen that are reminis-
cent to those seen in tissue sections incubated with ZASP
antibodies (Fig. 6 C). However, there are also cells that
show a pattern of strongly fluorescing dots similar to those
seen in undifferentiated cells, and these may in fact be
cells in the early stages of differentiation. A weak fluores-
cent signal can be detected in undifferentiated and differ-
entiated cells incubated with preimmune serum (Fig. 6, A
and B), as well as undifferentiated cells incubated with
myosin (Fig. 6 A). However, in differentiated cells incu-
bated with myosin (Fig. 6 B), strong fluorescence can be
detected in the cytoplasm near the nuclei and as cross-stri-
ations throughout the myotubes.
In tissue sections of human heart (not shown) and skele-
tal muscle (Fig. 6 C), an alternate banding pattern could
be detected by indirect immunofluorescence experiments
using antibodies to ZASP (red) and actin (green). From
double fluorescence experiments, the ZASP and actin sig-
nals seem to be coincident, as seen in Fig. 6 C, which
would suggest that the ZASP protein is present in the
I-band.
Immunoelectron microscopy of heart and skeletal mus-
cle tissue sections demonstrated that ZASP is located
within the Z-band, as can be seen in Fig. 7, A and B, the
latter showing a higher magnification of the same section.
Therefore, ZASP would appear to be present throughout
the Z-band.
Characterization of Alternative Forms of ZASP
The full-length cDNA sequence of ZASP was used to
search for similar sequences in the Genbank/EMBL/
DDBJ databases. Two regions of ZASP (322 and 203 bp)
were found to be identical to KIAA0613, as shown in Fig.
8. As mentioned previously, KIAA0613 is a sequence ob-
tained from systematic sequencing of a brain library (Ish-
ikawa et al., 1998). Interestingly, the 39 end region of
KIAA0613 matches perfectly with a cluster of ESTs from
the 39 end skeletal muscle catalogue mentioned above.
This cluster is referred to as HSPD1333 and contains
four ESTs, which are found with a frequency of 0.012%
(about five times less than ZASP). Therefore, we decided
to investigate further the following two points: is the
KIAA0613 actually expressed in muscle, as the 39 end tag
would indicate? And, are ZASP and KIAA0613 two alter-
natively spliced forms encoded by the same gene?
To verify whether the entire KIAA0613 is actually ex-
pressed in muscle, we screened by PCR our full-length
cDNA library of skeletal muscle, using two primers de-
signed respectively on the 59 and 39 end of the KIAA0613
sequence. As a result, we obtained two variant bands that
were sequenced, neither of which corresponded to the
KIAA0613 sequence (Fig. 8). An identical result was ob-
tained from a heart library. Therefore, we do not have any
evidence that KIAA0613 is expressed in skeletal muscle or
Figure 5. (A) Total protein obtained from in vitro translation of
muscle and control mRNAs using the rabbit reticulocyte lysate
system (Promega Corp.). Lanes: 1, negative control sample with
water instead of mRNA; 2, positive control, BMV mRNA; 3, hu-
man adult skeletal muscle mRNA; 4, human fetal skeletal muscle
mRNA; 5, human adult heart mRNA; and 6, human fetal heart
mRNA. (B) Immunoprecipitation of in vitro translated human
adult and fetal skeletal muscle proteins. (C) Immunoprecipita-
tion of in vitro translated human adult and fetal heart. Equal
amounts of [35S]methionine-labeled proteins were mixed with the
appropriate antibody and immunoprecipitated using protein
A–Sepharose, and were then run on SDS-polyacrylamide gels. In
B and C, the total in vitro translated human heart and muscle
proteins were immunoprecipitated with the antibodies denoted
by the corresponding lane numbers: 1, preimmune sera; 2, anti-
body to ZASP; and 3, antibody to myosin. Numbers on the left of
the figures indicate rainbow 14C-methylated protein molecular
weight markers, in kD.The Journal of Cell Biology, Volume 146, 1999 472
in heart. However, the two variant transcripts that were
identified give further support and complexity to the idea
of alternative splicing. In the schematic view presented in
Fig. 8, it can be seen that the four transcripts are composed
of different combinations of ten fragments. The perfect
identity of these fragments in the four transcripts, and the
way that they are assorted, is compatible with the hypothe-
sis of alternative splicing.
To address more specifically whether these transcripts
could have originated by alternative splicing from the
same gene, we amplified human genomic DNA using a
forward oligo designed on box 365 (see Fig. 8), and a re-
verse oligo designed on the 203-bp box. As a result, a band
.10,000 bases was obtained (data not shown). This band
was used as a template for a PCR reaction, directed by
primers specific for box 197 of ZASP, giving an amplified
fragment identical to that of a control performed on ge-
nomic DNA. This result confirms the hypothesis of alter-
native splicing and indicates that the putative exon corre-
sponding to box 197 of ZASP is located after the exon
with box 365 of KIAA0613.
The 39 end region of KIAA0613 was analyzed by the ra-
diation hybrid technique and found to map at 10q22.3-
10q23.2, the same position of the 39 end region of ZASP.
The PDZ Domain of ZASP Interacts with a-Actinin-2
To identify muscle proteins, which could bind to the PDZ
domain at the NH2-terminal of ZASP, three cDNA librar-
ies were screened by the yeast two-hybrid system.
The segment consisting of the first 321 coding bases of
ZASP was subcloned into the pHybridLex/Zeo vector as a
bait and transformed into L40 yeast strain. Then, 2,500,000
transformants were screened from various muscle librar-
ies: 280,000 clones from the pGAD10 human skeletal mus-
cle library (pGAD10S), 600,000 clones from the pGAD10
human heart library (pGAD10H), and 1,750,000 clones
from the pDisplayTarget human heart library (pDTH).
Growing clones were picked from the different librar-
ies: 17 clones from the pGAD10S, 9 clones from the
pGAD10H, and 87 clones from pDTH, and their interac-
tions confirmed with the b-galactosidase filter assay. The
Figure 6. Indirect immuno-
fluorescence of undifferenti-
ated human myoblasts (A)
and differentiated human myo-
tubes (B). Preimmune sera
and ZASP pAb were used at
a dilution of 1/50; myosin
mAb (MF 20) was used at
1/100 dilution. FITC-conju-
gated anti-mouse immuno-
globulin (Sigma Chemical
Co.) was used as the second
antibody. (C) Indirect immu-
nofluorescence of skeletal
muscle tissue sections using
mouse pAb to ZASP (1/30
dilution) and rabbit anti-
actin antibody (1/40). FITC-
labeled goat anti–rabbit Ig
(green) and TRITC-labeled
goat anti–mouse Ig (red)
were used as second antibod-
ies. Bars, 10 mm.Faulkner et al. ZASP: A New Skeletal Muscle Protein 473
inserts associated with the activation domains of the posi-
tive clones were directly amplified from yeast cells by PCR
and 30 were sequenced. The inserts of 23 clones were iden-
tified as fragments of the a-actinin-2 gene (Beggs et al.,
1992), whereas the other seven clones matched mitochon-
drial genes and transcription factors, typical false positives
of the yeast two-hybrid system.
All the clones containing a-actinin-2 cDNA, although
they start from different positions, extend to the end of the
coding region, as shown in Fig. 9. The region of a-actinin-2
binding to the PDZ domain of ZASP can be inferred from
the clones containing the shortest cDNA inserts that have
only the final 155 amino acids of the COOH-terminal re-
gion of the a-actinin-2 protein.
Discussion
From the data presented in this paper, it is evident that
in human heart and skeletal muscle there are at least
three different forms of ZASP, derived by alternative
splicing. A fourth form, also derived by alternative splic-
ing, is present in brain and was previously described as
KIAA0613 (Ishikawa et al., 1998). Furthermore, an EST
obtained from human fetal lung (GenBank/EMBL/DDBJ
accession number AI193732) indicates the presence of a
transcript in which the boxes of 322 and 203 bp of Fig. 8
are joined together. The presence of more variants of this
transcript in other tissues is suggested by Northern blot
analysis. For instance, in Fig. 2 A, it can be seen that using
the 39 end region of ZASP as a probe, a very strong signal
is also found in pancreas, producing a band smaller than
that seen in muscle. A faint band of z1 kb can be detected
also in placenta. Similarly, using a probe specific for the
322-bp box, several strong bands can be seen in muscle
and heart (Fig. 2 D). After overexposure (data not shown),
weak bands of different sizes can be seen in brain, small in-
testine, and placenta. These data suggest a complex case of
alternative splicing, producing a wide variety of transcripts
in different tissues, also confirmed at the protein level, as
shown in Fig. 3 B.
To approach the issue of the possible function of these
alternatively spliced transcripts, we tried to dissect the cor-
responding putative proteins on the basis of their alterna-
tively assorted fragments, as well as on any recognizable
Figure 7. Localization of ZASP in human skeletal muscle by immunoelectron microscopy. Immunoelectron microscopy with ZASP
pAb as the primary antibody and anti-mouse IgG whole molecule conjugated with 5-nm gold particles (Sigma Chemical Co.; G7527) as
the secondary antibody. (A) Low magnification of a section of skeletal muscle. The gold particles were detected in the Z-band. (B)
Higher magnification of the same image, rotated 908. The ZASP protein is seen throughout the Z-band. Bars, 0.1 mm.The Journal of Cell Biology, Volume 146, 1999 474
functional domains. The only domain that is common to
the different forms, that so far have been sequenced, is the
PDZ domain at the NH2 terminus, which is fully encoded
by the 322-base box shown in Fig. 8. As it was said in the
introduction, the PDZ domain is generally engaged in pro-
tein–protein interaction. To further investigate this issue,
we performed a yeast two-hybrid assay and discovered
that the PDZ domain of ZASP is interacting with the re-
gion extending across 150 COOH-terminal amino acids
of the Z-band protein a-actinin-2. This latter protein is
known to bind other Z-band proteins such as titin (Oht-
suka et al., 1997; Sorimachi et al., 1997; Young et al., 1998)
and ALP (Xia et al., 1997). Titin has been reported to bind
the region spanning the final 73 COOH-terminal amino
acids of a-actinin-2 (Ohtsuka et al., 1997; Sorimachi et al.,
1997), therefore, both ZASP and titin seem to bind a-acti-
nin-2 around the same region, near the COOH terminus.
However, recently it has been reported that titin can also
interact with the central spectrin-like repeat of a-actinin-2,
as well as with the COOH-terminal domain (Young et al.,
1998). The analogy between ZASP and ALP in binding
a-actinin-2 is also very interesting, as the PDZ domain
of ALP is one of the most similar to the PDZ domain
of ZASP, sharing 53/84 identical residues. Therefore, it
should not be surprising that both of these PDZ domains
bind a-actinin-2. However, it is strange that the PDZ of
ALP has been reported (Xia et al., 1997) to bind the spec-
trin-like domains 2 and 3 of a-actinin-2 (see map on Fig.
9), whereas the PDZ domain of ZASP binds to the
COOH-terminal region. Although we cannot exclude that
the PDZ domain of ZASP may also bind the spectrin-like
domains of a-actinin-2, this observation remains puzzling.
A second fragment that can be functionally dissected is
that of 1,061 bp (see Fig. 8), which encodes three LIM do-
mains, as detected by the program SMART (Schultz et al.,
1998). The LIM domains are also involved in protein–pro-
tein interaction. None of the other fragments are similar to
any known functional domain.
PDZ and LIM domains are often found associated on
the same proteins. In fact, using the program BLASTP
(Altschul et al., 1997) we searched the NCBI nonredun-
dant protein databases for similarity to the PDZ domain
of ZASP and we found that the 15 best hits (53–63% of
identities on an 80–84 amino acid overlap) are to PDZ do-
mains belonging to proteins containing LIM domains at
the COOH terminus. Some of these proteins have only a
single LIM domain, such as rat CLP36 (GenBank/EMBL/
DDBJ accession number U23769); human and mouse
CLIM1 (GenBank/EMBL/DDBJ accession numbers
U90878 and AF053367); mouse, human, and rat RIL
(GenBank/EMBL/DDBJ accession numbers Y08361,
X93510, and X76454); and human, mouse, and rat ALP
(GenBank/EMBL/DDBJ accession numbers AF002280 to
AF002283). The remaining proteins have an organization
similar to the variant forms of ZASP, in which the PDZ
domain is followed by three LIM domains (see Fig. 8).
These proteins are the LIM protein itself (GenBank/
EMBL/DDBJ accession AF061258), human and rat
Enigma (GenBank/EMBL/DDBJ accession numbers
L35241 and U48247), and rat LMP1 (GenBank/EMBL/
DDBJ accession number AF095585).
Figure 8. Schematic repre-
sentation of the ZASP tran-
script, two alternative muscle
variants, and brain transcript
KIAA0613. Boxes (not al-
ways in scale) represent the
coding region and the num-
bers inside each box indicate
the length in bases. The 39
and 59 untranslated regions
are represented by the ter-
minal lines. The original
KIAA0613 sequence begins
just a few bases in front of
the first ATG starting codon.
However, the box has been
marked as 322 bases long to
facilitate the interpretation.
Figure 9. Schematic representation of the positive a-actinin-2
clones found using the yeast two-hybrid system. The domains of
a-actinin-2 are shown at the top, whereas the remaining part of
the figure shows the coding regions of the a-actinin-2, which are
involved in a positive interaction with the PDZ domain of ZASP.
The numbers at the side of the bars indicate the starting amino
acid. The coding regions of all the a-actinin-2 clones reach the
true stop codon of the protein at position 894.Faulkner et al. ZASP: A New Skeletal Muscle Protein 475
A similar result was obtained when the sequence con-
taining the three LIM domains of the variant forms of
ZASP was used as a query for a BLASTP search. The best
hits returned were the same Enigma, LIM, and LPM1 pro-
teins seen above, showing alignments of 174–178 amino
acids with a percentage of identity ranging from 58% to
67%. None of the other boxes of Fig. 8 show any signifi-
cant similarity to known proteins, with the exception of
the 197-bp box that shows similarity (45% identity on a 51
amino acids overlap) with the skeletal muscle isoforms of
ALP. In fact, ALP is found as two isoforms derived from
alternative splicing.
Another intriguing feature is the presence in the 203-bp
box (which is common to all the ZASP isoforms shown in
Fig. 8) of a conserved stretch of 15 amino acids (QSRSF-
RILAQMTGTE), which is also found in the human LIM
and in rat Enigma proteins.
A suggestive speculation is that, in general, these PDZ/
LIM proteins could act as some kind of adapters (Cuppen
et al., 1998). The data presented in this paper give further
support to this hypothesis, adding an extended degree of
modularity by means of an intricate alternative splicing. In
this scheme, the idea of ZASP as a truncated form of a
PDZ/LIM adapter does not exclude the possibility that
this protein may act as a competitor against the two other
variant forms found in muscle, which have the LIM do-
mains.
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